BRPI0608138A2 - cloridrato de lercanidipina amorfa - Google Patents

cloridrato de lercanidipina amorfa

Info

Publication number
BRPI0608138A2
BRPI0608138A2 BRPI0608138-0A BRPI0608138A BRPI0608138A2 BR PI0608138 A2 BRPI0608138 A2 BR PI0608138A2 BR PI0608138 A BRPI0608138 A BR PI0608138A BR PI0608138 A2 BRPI0608138 A2 BR PI0608138A2
Authority
BR
Brazil
Prior art keywords
pure
amorphous lercanidipine
lercanidipine hydrochloride
amorphous
hydrochloride
Prior art date
Application number
BRPI0608138-0A
Other languages
English (en)
Inventor
Amedeo Leonardi
Gianni Motta
Fabio Berlati
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36585434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0608138(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of BRPI0608138A2 publication Critical patent/BRPI0608138A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/04—Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

CLORIDRATO DE LERCANIDIPINA AMORFA. A invenção apresenta um cloridrato de lercanidipina amorfa substancialmente puro, com uma pureza de pelo menos 95% puro, de preferência pelo menos cerca de 97% puro, mais preferivelmente pelo menos cerca de 99% puro e, ainda mais preferivelmente, pelo menos cerca de 99,5% puro. A invenção também apresenta métodos de preparação de lercanidipina amorfa substancialmente pura e composições farmacêuticas contendo a lercanidipina amorfa substancialmente pura.
BRPI0608138-0A 2005-02-25 2006-02-24 cloridrato de lercanidipina amorfa BRPI0608138A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65683605P 2005-02-25 2005-02-25
PCT/EP2006/001782 WO2006089787A1 (en) 2005-02-25 2006-02-24 Amorphous lercanidipine hydrochloride

Publications (1)

Publication Number Publication Date
BRPI0608138A2 true BRPI0608138A2 (pt) 2009-11-17

Family

ID=36585434

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608138-0A BRPI0608138A2 (pt) 2005-02-25 2006-02-24 cloridrato de lercanidipina amorfa

Country Status (32)

Country Link
US (1) US7820701B2 (pt)
EP (1) EP1856051B1 (pt)
JP (1) JP2008531515A (pt)
KR (1) KR20070105979A (pt)
CN (1) CN101124204A (pt)
AR (1) AR052918A1 (pt)
AU (1) AU2006218026B9 (pt)
BR (1) BRPI0608138A2 (pt)
CA (1) CA2598016A1 (pt)
CY (1) CY1122429T1 (pt)
DK (1) DK1856051T3 (pt)
EA (1) EA014383B1 (pt)
ES (1) ES2339213T3 (pt)
HR (1) HRP20192302T1 (pt)
HU (1) HUE046910T2 (pt)
IL (1) IL184349A0 (pt)
LT (1) LT1856051T (pt)
ME (1) ME03659B (pt)
MX (1) MX2007010093A (pt)
MY (1) MY142129A (pt)
NO (1) NO344559B1 (pt)
NZ (1) NZ556667A (pt)
PE (1) PE20061014A1 (pt)
PL (1) PL1856051T3 (pt)
PT (1) PT1856051T (pt)
RS (1) RS59654B1 (pt)
SI (1) SI1856051T1 (pt)
TW (1) TW200640861A (pt)
UA (1) UA90130C2 (pt)
UY (1) UY29401A1 (pt)
WO (1) WO2006089787A1 (pt)
ZA (1) ZA200708127B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532248B1 (en) 2002-07-26 2009-04-01 Novartis Vaccines and Diagnostics, Inc. Modified small interfering rna molecules and methods of use
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
KR20080048065A (ko) 2005-09-16 2008-05-30 그렌마크 파머수티칼스 엘티디. 다형 형태의 염산 레르카니디핀 및 이것의 제조방법
DK2046745T3 (da) * 2006-08-04 2014-01-20 Recordati Ireland Ltd Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid
EP2101771A2 (en) * 2006-12-06 2009-09-23 Torrent Pharmaceuticals Ltd Stable lercanidipine formulation
EP2121575A2 (en) * 2007-03-05 2009-11-25 Actavis Group PTC EHF Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate
ES2531040T3 (es) * 2009-05-12 2015-03-10 Corcept Therapeutics Inc Formas sólidas y procedimiento de preparación
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
EP3039011A1 (en) * 2013-08-29 2016-07-06 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IT1274480B (it) 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US5912351A (en) 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
ITMI20011727A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
US20030069285A1 (en) * 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US20030180355A1 (en) * 2001-10-16 2003-09-25 Amedeo Leonardi Combination therapy for hypertension
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
TW200616681A (en) 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
KR20080048065A (ko) 2005-09-16 2008-05-30 그렌마크 파머수티칼스 엘티디. 다형 형태의 염산 레르카니디핀 및 이것의 제조방법
EP1963254A2 (en) 2005-09-21 2008-09-03 Torrent Pharmaceuticals Ltd Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
DK2046745T3 (da) 2006-08-04 2014-01-20 Recordati Ireland Ltd Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid

Also Published As

Publication number Publication date
AU2006218026B2 (en) 2009-04-02
PE20061014A1 (es) 2006-10-03
KR20070105979A (ko) 2007-10-31
AU2006218026B9 (en) 2011-10-27
PL1856051T3 (pl) 2020-05-18
US7820701B2 (en) 2010-10-26
NZ556667A (en) 2009-10-30
PT1856051T (pt) 2020-01-07
EP1856051A1 (en) 2007-11-21
RS59654B1 (sr) 2020-01-31
CN101124204A (zh) 2008-02-13
WO2006089787A1 (en) 2006-08-31
TW200640861A (en) 2006-12-01
LT1856051T (lt) 2020-01-10
IL184349A0 (en) 2007-10-31
ES2339213T3 (es) 2020-05-28
AU2006218026A1 (en) 2006-08-31
HRP20192302T1 (hr) 2020-03-06
EA200701687A1 (ru) 2008-02-28
ME03659B (me) 2021-01-20
JP2008531515A (ja) 2008-08-14
CY1122429T1 (el) 2021-01-27
EA014383B1 (ru) 2010-10-29
EP1856051B1 (en) 2019-11-13
NO344559B1 (no) 2020-02-03
NO20074874L (no) 2007-11-26
US20060211742A1 (en) 2006-09-21
UA90130C2 (ru) 2010-04-12
UY29401A1 (es) 2006-06-30
ZA200708127B (en) 2008-11-26
DK1856051T3 (da) 2020-01-02
MY142129A (en) 2010-09-30
CA2598016A1 (en) 2006-08-31
HUE046910T2 (hu) 2020-04-28
MX2007010093A (es) 2007-10-12
AR052918A1 (es) 2007-04-11
SI1856051T1 (sl) 2020-02-28
ES2339213T1 (es) 2010-05-18

Similar Documents

Publication Publication Date Title
BRPI0608138A2 (pt) cloridrato de lercanidipina amorfa
GEP20084467B (en) Gamma crystalline form of ivabradine hydrochloride, process for its preparation and pharmaceutical compositions containing it
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
MXPA05012680A (es) Indoles novedosos de 3-azufre sustituidos.
SG162804A1 (en) Pyrazole based lxr modulators
DK1845954T3 (da) Oralt opløsende sammensætning af olanzapin og donepzil
CY1117051T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικη μορφη (i) της υδροχλωριουχου λερκανιδιπινης
UA97502C2 (ru) Кристаллическая твердая основа разагилина
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
TW200716163A (en) A therapeutic agent for aβ related disorders
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
RS36904A (en) Polymorphous form or rimonabant,preparation method and pharmaceutical, compositions containing same
ATE413875T1 (de) Zusammensetzungen enthaltend levetiracetam und verfahren zu deren herstellung.
EP1831239B8 (en) A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid gamma-lactone and key-intermediates for this process
BRPI0610156A2 (pt) forma micronizada de um composto, forma purificada i do composto, kit, padrão de referência, e, método de preparaçao de uma composição farmacêutica.
MY149864A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
TW200640860A (en) Lercanidipine free base
WO2006004903A3 (en) 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
HUP0401161A2 (hu) Lerkanidipin-hidroklorid szolvátjai és lerkanidipin-hidroklorid új kristályos formái, eljárás előállításukra és a kristályos formákat tartalmazó gyógyászati készítmények
DE60212130D1 (en) Carvedilolpolymorph
WO2007022173A3 (en) Crystalline forms fenoldopam mesylate
WO2007052167A3 (en) Stable composition for a pharmaceutical formulation containing olanzapine
BRPI0508279A (pt) composições de peróxido estabilizadas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL